Chapter 8 - My Two-Billion-Dollar Deal Was Not the Victory Everyone Thought
The media called me a genius.
They called the launch sabotage “the most dramatic biotech reversal in a decade.”
Headlines loved the number.
$2 billion.
What they ignored was the structure.
Orchid Biomedical did not hand me two billion dollars.
The agreement included:
$400 million upfront.
$600 million in development milestones.
Up to $1 billion tied to regulatory and commercial performance.
Hart Research Trust retained significant research obligations.
If Aurum 2 failed, most of that money would never arrive.
I preferred it that way.
Science should not become mythology because a contract contains a large number.
Then another complication emerged.
Aurum 2 was not ready for human use.
Not close.
The perfected platform meant better preclinical performance.
Not a miracle cure.
Cassandra had spent months overselling Aurum 1 to investors.
Language like revolutionary.
Paradigm-shifting.
Transform medicine forever.
My own team had warned against some claims.
She ignored them.
Why?
Valuation.
Halcyon planned a major financing round after the launch.
The higher Aurum’s perceived certainty, the higher the company valuation.
Julian helped approve projections.
That created another exposure.
Not necessarily fraud by itself.
Projections include risk.
But internal emails showed scientific caveats were repeatedly removed from investor materials.
I had objected.
Cassandra told communications to “simplify.”
Julian approved.
The board had never seen the original versions.
Now they did.
Halcyon’s crisis expanded.
Not simply stolen IP.
Governance.
Disclosure.
Controls.
Then one pharmaceutical company withdrew from partnership discussions.
Another paused.
Employees panicked.
Hundreds of people who had nothing to do with Cassandra’s actions suddenly faced uncertainty.
That mattered to me.
I founded Halcyon.
People had moved families to work there.
Researchers had built careers around our programs.
Destroying the company to punish Cassandra would hurt them too.
The board asked if Hart Research would restore a limited Aurum 1 license.
My attorney said:
“You don’t owe them anything.”
True.
But revenge was not my objective.
I proposed a temporary license.
Strict oversight.
Independent compliance.
No Cassandra.
No Julian in financial control.
Milestone-based rights.
The board accepted.
My decision angered Orchid.
They worried I was preserving a competitor.
I answered:
“Orchid bought Aurum 2. Not my right to prevent collateral damage.”
That negotiation became ugly.
Good.
Serious agreements should survive disagreement.
Then my vision began changing.
Not dramatically.
Light.
First only brightness.
Then vague shapes through my right eye after Dr. Ross removed part of the bandaging.
I could distinguish window from wall.
Person from doorway.
Nothing more.
The first face-shaped blur I saw belonged to Leah.
Not Julian.
That mattered somehow.
Then she handed me another report.
Cassandra had transferred $3.7 million from Halcyon’s strategic reserve into an investment vehicle eighteen days before the explosion.
Board approval:
Pending.
Recipient:
Vale-Hart Ventures.
I stared.
Hart.
Julian’s name was in the entity.
May you like
This wasn’t only about control of patents.
They had already started building the company they intended to run after pushing me aside.
